Wanbury expands global API reach with DMF filings and clean Korea FDA audit

1 min read Updated on 10 Jun 2026, 03:42 AM

Reviewed by

Shriram SScanX News Team

AI Summary

Wanbury Limited expanded its global API reach by submitting Drug Master Files for Diphenhydramine HCl in Malaysia and Singapore, and planning submissions for Paroxetine HCl in Korea and Latin America. The company's Patalganga facility secured a zero-observation audit report from the Ministry of Food and Drug Safety, Korea FDA, following an inspection in April 2026.

*this image is generated using AI for illustrative purposes only.

Wanbury Limited announced on June 9, 2026, that it has expanded its regulatory submissions for new Active Pharmaceutical Ingredients (APIs) to strengthen its presence in global markets. The company submitted Drug Master Files (DMFs) for Diphenhydramine HCl to Malaysia and Singapore. Additionally, Wanbury proposed to explore new market opportunities for Paroxetine HCl in Korea and Latin America by submitting DMFs in these regions.

Regulatory Approvals and Facility Audit

The company received a formal audit report from the Ministry of Food and Drug Safety (MFDS), Korea FDA, for its Patalganga facility. The report stated zero observations for the inspection conducted in April 2026. This follows the company's earlier financial disclosure for the year ended 31 March 2026, where it reported a 116.6% surge in net profit to ₹66.1 crore, driven by operational efficiency and new product launches.

Financial Performance Summary

Wanbury's audited financial results for FY26 showed revenue from operations rising to ₹650.3 crore from ₹599.5 crore in the previous year. EBITDA grew 34.9% to ₹107.7 crore. The board approved these results at its meeting on May 29, 2026.

Metric:	FY26	FY25	Q4 FY26	Q4 FY25
Net Profit:	₹66.1 crore	₹30.5 crore	₹21.7 crore	₹20.3 crore
Revenue from Operations:	₹650.3 crore	₹599.5 crore	₹164.6 crore	₹172.0 crore
EBITDA*:	₹107.7 crore	₹79.8 crore	₹30.1 crore	₹31.5 crore
EPS:	₹20.55	₹9.32	-	-

*Includes Other Income

Historical Stock Returns for Wanbury

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.70%	+2.39%	-3.21%	+14.94%	-1.53%	+182.84%

What is the expected timeline for regulatory approval of the DMFs submitted to Malaysia, Singapore, Korea, and Latin America?

How will the zero observations from the Korea FDA audit impact Wanbury's ability to secure new partnerships in the Asian market?

What are the projected revenue contributions from the new Diphenhydramine HCl and Paroxetine HCl markets over the next fiscal year?

Read Next Article

Wanbury Limited schedules analyst meet and site visit on June 5

1 min read Updated on 03 Jun 2026, 12:54 AM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

AI Summary

Wanbury Limited has scheduled a plant visit and management meeting for investors and analysts on June 5, 2026. The physical meeting will cover past financial results and public domain information. The schedule is subject to change due to exigencies.

*this image is generated using AI for illustrative purposes only.

Wanbury Limited has scheduled a plant visit and management meeting for investors and analysts on June 5, 2026. The event, organized under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, aims to provide stakeholders with insights into the company's operations. The meeting will be conducted physically at the company's facility.

The discussion during the session will cover the company's past financial results and other information already available in the public domain. This initiative allows investors and analysts to gain a direct understanding of the company's manufacturing capabilities and operational progress.

The schedule for the meeting is as follows:

Date	Type of meeting	Name of Investors / analysts	Mode of meeting
05.06.2026	Group meeting - Site visit	Group of Investors	Physical meeting

Wanbury noted that the schedule is subject to change due to exigencies. This includes potential adjustments in case of last-minute cancellations or a drop in participation from investors or brokers. The company will proceed with the event as planned unless such circumstances arise.

The disclosure was submitted to BSE Limited and the National Stock Exchange of India Ltd. The company's registered office is located at BSEL Tech Park, B-wing, 10th Floor, Sector-30 A, Vashi Navi Mumbai.

Historical Stock Returns for Wanbury